Prospective identification of biologically active structures by topomer shape similarity searching

被引:84
作者
Cramer, RD
Poss, MA
Hermsmeier, MA
Caulfield, TJ
Kowala, MC
Valentine, MT
机构
[1] Tripos Inc, St Louis, MO 63366 USA
[2] Bristol Myers Squibb, Princeton, NJ 08546 USA
关键词
D O I
10.1021/jm990159q
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The principle of bioisosterism-similarly shaped molecules are more likely to share biological properties than are other molecules-has long helped to guide drug discovery. An algorithmic implementation of this principle, based on shape comparisons of a single rule-generated "topomer" conformation per molecule, had been found to be the descriptor most consistently predictive of similar biological properties, in retrospective studies, and also to be well-suited for searching large (>10(12)) "virtual libraries" of potential reaction products. Therefore a prospective trial of this shape similarity searching method was carried out, with synthesis of 425 compounds and testing of them for inhibition of binding of angiotensin II (A-II). The 63 compounds that were identified by shape searching as most similar to any of four query structures included all of the seven compounds found to be highly active, with none of the other 362 structures being highly active (p < 0.001). Additional consistent relations (p < 0.05) were found, among all 425 compounds, between the degree of shape similarity to the nearest query structure and the frequency of various levels of observed activity. Known "SAR" (rules specifying structural features required for A-II antagonism) were also regenerated within the biological data for the 63 shape similar structures.
引用
收藏
页码:3919 / 3933
页数:15
相关论文
共 27 条
[11]  
Ferguson A. M., 1996, J BIOMOL SCREEN, V1, P65
[12]  
GANELLIN CR, 1993, MED CHEM ROLE ORGANI, P227
[13]   A QUANTITATIVE APPROACH TO BIOCHEMICAL STRUCTURE-ACTIVITY RELATIONSHIPS [J].
HANSCH, C .
ACCOUNTS OF CHEMICAL RESEARCH, 1969, 2 (08) :232-&
[14]   Structure-based design and combinatorial chemistry yield low nanomolar inhibitors of cathepsin D [J].
Kick, EK ;
Roe, DC ;
Skillman, AG ;
Liu, GC ;
Ewing, TJA ;
Sun, YX ;
Kuntz, ID ;
Ellman, JA .
CHEMISTRY & BIOLOGY, 1997, 4 (04) :297-307
[15]  
Kubinyi H., 1997, 3D QSAR in Drug Design
[16]   NONPEPTIDE ANGIOTENSIN-II RECEPTOR ANTAGONISTS - SYNTHETIC AND COMPUTATIONAL CHEMISTRY OF N-[[4-[2-(2H-TETRAZOL-5-YL)-1-CYCLOALKEN-1-YL]PHENYL]METHYL]IMIDAZOLE DERIVATIVES AND THEIR INVITRO ACTIVITY [J].
LIN, HS ;
RAMPERSAUD, AA ;
ZIMMERMAN, K ;
STEINBERG, MI ;
BOYD, DB .
JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (14) :2658-2667
[17]  
MARTIN YC, 1997, 3D QSAR DRUG DESIGN, P3
[18]   MOLECULAR SHAPE COMPARISON OF ANGIOTENSIN-II RECEPTOR ANTAGONISTS [J].
MASEK, BB ;
MERCHANT, A ;
MATTHEW, JB .
JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (09) :1230-1238
[19]   Selecting optimally diverse compounds from structure databases: A validation study of two-dimensional and three-dimensional molecular descriptors [J].
Matter, H .
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (08) :1219-1229
[20]   Bioisosterism: A rational approach in drug design [J].
Patani, GA ;
LaVoie, EJ .
CHEMICAL REVIEWS, 1996, 96 (08) :3147-3176